对于体外受精（IVF）或配子输卵管内移植（GIFT）促排卵失败的患者，在人绝经期促性腺激素中添加布舍瑞林。

Addition of Buserelin to human menopausal gonadotrophins in patients with failed stimulations for IVF or GIFT.

作者信息

Smitz J, Devroey P, Camus M, Khan I, Staessen C, Van Waesberghe L, Wisanto A, Van Steirteghem A C

机构信息

Centre for Reproductive Medicine, Vrije Universiteit Brussel, Belgium.

出版信息

Hum Reprod. 1988 Oct;3 Suppl 2:35-8. doi: 10.1093/humrep/3.suppl_2.35.

DOI:10.1093/humrep/3.suppl_2.35

PMID:3147990

Abstract

The combined therapy of a gonadotrophin-releasing hormone agonist (GnRHa) D-Ser(TBU)6-EA10-LHRH (Buserelin) and human menopausal gonadotrophins (HMG) for ovarian stimulation for in-vitro fertilization and gamete intra-Fallopian transfer was evaluated during 84 cycles. All women selected for this therapy had previously failed stimulations with clomiphene citrate/HMG. The GnRHa prevented spontaneous luteinizing hormone surges and premature luteinization in all patients. After addition of the agonist to HMG, the cancellation rate dropped from 17 to 7% and improved the results in 72.6% of the cycles. Twenty-six per cent of the started cycles resulted in a pregnancy. Eighteen healthy children were born at term.

摘要

在84个周期中评估了促性腺激素释放激素激动剂（GnRHa）D-丝氨酸（叔丁基）6-EA10-促黄体生成素释放激素（布舍瑞林）与人绝经期促性腺激素（HMG）联合用于体外受精和配子输卵管内移植的卵巢刺激治疗。所有选择这种治疗方法的女性之前使用枸橼酸氯米芬/HMG刺激均失败。GnRHa可防止所有患者自发的促黄体生成素激增和过早黄素化。在HMG中加入激动剂后，取消率从17%降至7%，72.6%的周期结果得到改善。26%的启动周期成功妊娠。18名健康婴儿足月出生。